Contact
Please use this form to send email to PR contact of this press release:
Dupixent® (dupilumab) eosinophilic esophagitis trial meets both co-primary endpoints
TO:
Please use this form to send email to PR contact of this press release:
Dupixent® (dupilumab) eosinophilic esophagitis trial meets both co-primary endpoints
TO: